Effectivity and safety of PD-1/PD-L1 inhibitors for different level of PD-L1-positive, advanced NSCLC: A meta-analysis of 4939 patients from randomized controlled trials
- 1 July 2020
- journal article
- research article
- Published by Elsevier BV in International Immunopharmacology
- Vol. 84, 106452
- https://doi.org/10.1016/j.intimp.2020.106452
Abstract
No abstract availableThis publication has 27 references indexed in Scilit:
- Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in ChinaJournal of Hematology & Oncology, 2017
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialThe Lancet, 2016
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2016
- The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor CharacteristicsJournal of Thoracic Oncology, 2016
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialThe Lancet, 2016
- Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b studyThe Lancet Oncology, 2016
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 2015
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2015
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2015
- Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1Value in Health, 2011